Arcus, Gilead prep Phase III studies of anti-TIGIT domvanalimab
24th June 2021 Uncategorised 0Preparations come on the heels of positive results from the Phase II ARC-7 study
More: Arcus, Gilead prep Phase III studies of anti-TIGIT domvanalimab
Source: News
